Table 3.
Oxidative status in the study groups
| CRF | HD | PD | |
|---|---|---|---|
| TBARS (μmol.L-1) | 0.12 ± 0.01 | 0.23 ± 0.02* | 0.18 ± 0.01* |
| TBARS-VLDL (μmol.L-1) | 0.55 ± 0.02 | 0.10 ± 0.05** | 0.026 ± 0.014** |
| TBARS-LDL (μmol.mL1) | 0.038 ± 0.002 | 0.055 ± 0.023* | 0.052 ± 0.014* |
| TBARS-HDL2 (μmol.mL1) | 0.09 ± 0.01 | 0.047 ± 0.008* | 0.023 ± 0.01*# |
| TBARS-HDL3 (μmol.mL1) | 0.196 ± 0.05 | 0.105 ± 0.070 | 0.231 ± 0.049 |
| Carbonyls (μmol.mL1) | 0.3 ± 0.16 | 0.92 ± 0.15* | 1.90 ± 0.10**## |
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis. PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD. * HD group and PD group vs CRF group # HD group vs PD group. *#(P < 0.05); **##(P < 0.01)